Xencor Inc (XNCR): Results of Operations and Financial Condition
Xencor Inc (XNCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ® Designing Proteins Delivering Medicines Updated Results from Dose Expansion Cohorts in the Phase 1 Study of XmAb819 October 26, 2026 2 Today's Speakers Bassil Dahiyat, Ph.D. President & Chief Executive Officer Xencor Management Guest Speaker Sumanta Pal, M.D., F.A.
How this was made
The 30-second read
Why it matters
The disclosure provides fresh material that could move the stock as investors reassess the drug's development timeline and market potential.
Market read
First‑report of trial data creates a short‑term trading catalyst for XNCR.
What to watch
Potential delays in later‑stage trials or competitive pipeline advances.
Updated Results from Dose Expansion Cohorts in the Phase 1 Study of XmAb819
XmAb819 showed confirmed objective response rates of 30.0%, 44.0% and 45.5% across the 100 μg/kg, 200 μg/kg and 400 μg/kg target-dose cohorts, respectively, but the expansion-dose safety dataset reported Grade ≥3 TEAEs in 56 (82.4%) subjects and serious TEAEs in 42 (61.8%) subjects.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| XmAb819 100 μg/kg target-dose cohort confirmed ORRother | 30.0 (14.7, 49.4) | – | – |
| XmAb819 100 μg/kg target-dose cohort disease control rateother | 86.7 (69.3, 96.2) | – | – |
| XmAb819 100 μg/kg target-dose cohort median follow-upother | 4.1 (1.1, 28.3) months | – | – |
| XmAb819 200 μg/kg target-dose cohort confirmed ORRother | 44.0 (24.4, 65.1) | – | – |
| XmAb819 200 μg/kg target-dose cohort disease control rateother | 64.0 (42.5, 82.0) | – | – |
| XmAb819 200 μg/kg target-dose cohort median follow-upother | 4.5 (0.8, 11.6) months | – | – |
| XmAb819 400 μg/kg target-dose cohort confirmed ORRother | 45.5 (16.8, 76.6) | – | – |
| XmAb819 400 μg/kg target-dose cohort disease control rateother | 81.8 (48.2, 97.7) | – | – |
| XmAb819 400 μg/kg target-dose cohort median follow-upother | 6.0 (1.4, 7.9) months | – | – |
| Expanded-dose responders with ongoing responsesother | 19 (76.0) | – | – |
| Expanded-dose responders median time to responseother | 2.7 (1.3, 20.9) months | – | – |
| Expanded-dose responders median time on treatmentother | 7.0 (3.4, 28.3) months | – | – |
| Consolidated IV target-dose population median time on treatmentother | 7.9 month | – | – |
| Expanded-dose cohort Grade ≥3 TEAEsother | 56 (82.4) | – | – |
| Expanded-dose cohort related Grade ≥3 TEAEsother | 49 (72.1) | – | – |
| Expanded-dose cohort serious TEAEsother | 42 (61.8) | – | – |
| Expanded-dose cohort related serious TEAEsother | 37 (54.4) | – | – |
| Expanded-dose cohort TEAEs leading to discontinuationother | 5 (7.4) | – | – |
| Expanded-dose cohort treatment-emergent adverse events leading to deathother | 0 | – | – |
1H 2027 and YE2027 outlook
- NotePresent subcutaneous dosing and full 400 μg/kg intravenous dosing cohort data 1H 2027
- NoteEnd of Phase 1 meeting to inform potential accelerated approval pathway and design for potential global RCT using tivozanib control arm to support BLA seeking potential full approval following a PD(L)1 inhibitor and VEGFR - TKI 1H 2027
- NoteInitiation of first registration - enabling study targeted by YE2027
- NotePresent first data from post 1L IO - IO for IMDC intermediate/poor risk patients 2027
- NoteContinue enrollment of ENPP3+ basket study (pRCC, CRC and NSCLC) 2027
- NotePrimary endpoint analysis in ~2H27
What drove it
- XmAb819 is an ENPP3 x CD3 bispecific antibody being evaluated in advanced clear cell renal cell carcinoma.
- Antitumor activity was reported across 100 μg/kg, 200 μg/kg and 400 μg/kg target-dose cohorts.
- Among expanded-dose patients with prior HIF2α inhibitor exposure, confirmed ORR was 34.8 (16.4, 57.3) and disease control rate was 78.3 (56.3, 92.5).
- Among expanded-dose patients with prior ≥2 VEGFR-TKIs, confirmed ORR was 45.2 (29.9, 61.3) and disease control rate was 85.7 (71.5, 94.6).
- The company identified 400 μg/kg as the proposed IV RP3D for XmAb819.
Concerns
- The 400 μg/kg efficacy-evaluable cohort contained 11 subjects, with median follow-up of 6.0 (1.4, 7.9) months.
- In the expansion-dose cohort, rash occurred in 62 (91.2) subjects, cytokine release syndrome occurred in 46 (67.6) subjects, ALT increased in 36 (52.9) subjects, and AST increased in 33 (48.5) subjects.
- Grade ≥3 ALT increased occurred in 23 (33.8) expansion-dose subjects and Grade ≥3 AST increased occurred in 24 (35.3) subjects.
- Dose delays due to transaminase elevations occurred in 14.7% of subjects, and dose delays due to rash occurred in 4.4% of subjects.
- The filing states that the proposed registration study design and registrational potential are subject to further interactions with FDA.
What to watch
- Full 400 µg/kg IV analysis set data expected during 1H2027 (20+ patients).
- End of Phase 1 meeting in 1H 2027.
- Subcutaneous dosing data in 1H 2027.
- First data from post 1L IO - IO for IMDC intermediate/poor risk patients in 2027.
- Potential initiation of the first registration-enabling study by YE2027.
- Continued enrollment of the ENPP3+ basket study in pRCC, CRC and NSCLC.
Balance sheet and cash flow
- Cash runway into 2029
Analysis
This filing is a clinical-development update rather than an earnings release. It reports Phase 1 dose-expansion data for XmAb819 in advanced clear cell renal cell carcinoma, with efficacy-evaluable cohorts of 30 subjects at 100 μg/kg, 25 subjects at 200 μg/kg and 11 subjects at 400 μg/kg. Confirmed ORR was 30.0 (14.7, 49.4), 44.0 (24.4, 65.1) and 45.5 (16.8, 76.6), respectively. Disease control rate was 86.7 (69.3, 96.2), 64.0 (42.5, 82.0) and 81.8 (48.2, 97.7), respectively.
The 400 μg/kg target dose is the proposed IV RP3D. The company reported 45% cORR, >80% DCR, >70% of patients with treatment ongoing, ~82% 6-month PFS K-M estimate and median PFS not reached for this dose in a data set cut October 1, 2026. However, the cohort-specific efficacy table reports 11 efficacy-evaluable subjects and median follow-up of 6.0 (1.4, 7.9) months. The presentation also states that the full 400 µg/kg IV analysis set is expected during 1H2027.
The safety profile remains the principal issue to monitor. In the 68-subject expansion-dose population, 56 (82.4) experienced Grade ≥3 TEAEs, 49 (72.1) experienced related Grade ≥3 TEAEs, and 42 (61.8) experienced serious TEAEs. Rash, cytokine release syndrome and liver-enzyme elevations were frequent. At the same time, 5 (7.4) subjects had a TEAE leading to discontinuation, 4 (5.9) had a related TEAE leading to discontinuation, and there were 0 treatment-emergent adverse events leading to death.
The program is moving toward regulatory and development milestones rather than financial guidance. Xencor plans an end-of-Phase-1 meeting in 1H 2027, expects subcutaneous dosing and full 400 μg/kg cohort data in 1H 2027, and targets initiation of its first registration-enabling study by YE2027. The filing also identifies ongoing enrollment in ENPP3-positive basket cohorts in papillary RCC, MSS colorectal cancer and NSCLC, as well as planned data from a post-1L IO-IO setting in 2027.
No income statement, balance sheet, cash flow statement, capital-return activity, quarterly revenue, earnings per share or conventional financial outlook was included. The only financial-resource statement is that the company has cash runway into 2029. Accordingly, the update provides clinical evidence and development timing but does not provide reported financial performance for an earnings-period assessment.
Not in the filing
stated, not guessed- Fiscal period end date
- Total revenue
- Revenue by segment
- Gross margin
- Operating expenses
- Operating income or loss
- Net income or loss
- GAAP EPS
- Non-GAAP EPS
- Operating cash flow
- Free cash flow
- Cash balance
- Debt balance
- Share repurchases
- Dividends
- Tax rate
- Financial revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Prior-period financial results
- Prior outlook for comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Xencor filed an 8‑K reporting Phase 1 expansion cohort results for its ENPP3×CD3 bispecific XmAb819 targeting renal cell carcinoma.
Ticker impact
SEC 8‑K filing discloses updated Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma.
potential modest upside as market absorbs positive trial updates
First‑report of Phase 1 expansion data; biotech stocks typically react to trial milestones.
Market effects
May boost sentiment for other bispecific antibody developers.
Limited to US biotech sector.
Low; relevance confined to specialty oncology investors.
Counterpoint
If data are modest, the stock could face disappointment and short pressure.
Key entities
- companyXencor Inc.
Biotech firm developing bispecific T‑cell engagers.
